After rejecting the weight-loss drug Qnexa in 2010, the Food and Drug Administration is examining new knowledge to work out whether or not the drug ought to be approved.
Next week, the Food and Drug Administration is ready to review the security and effectiveness of the disputable weight-loss drug Qnexa, whose makers, Vivius Inc., ar pushing to form Qnexa the primary new FDA-approved weight-loss supplement since 1999.
The FDA originally reviewed Qnexa as a treatment for weight loss in 2010, however turned it down over safety considerations, together with doable heart issues associated an redoubled risk of birth defects. per the Wall Street Journal, alternative studies of 1 of Qnexa’s active ingredients, topirmate, have urged associate redoubled birth-defect risk. In response, Vivius at the start planned limiting the drug to men and girls of nonchild-bearing age.
After the initial rejection, the FDA asked Vivus for a further assessment of the drug’s potential damage — a typical observe in FDA drug proceedings — and currently, Vivus reports the drug isn't solely safe, however additionally effective in manufacturing vital weight loss. Next week’s review of the drug can embody knowledge from a biennial trial, as opposition just one year’s price of knowledge, that was what was reviewed in 2010. The new trial knowledge found that the drug was prosperous in manufacturing weight loss throughout the primary year of use, however that some participants did regain some weight throughout the second year of the trial.
The 2010 rejection of Qnexa {and several|and a number of alternative|and several other} other diet medication thrust the FDA’s approval method for weight-loss medication into the spotlight at a time once fleshiness continues to be a nationwide health crisis. In recent years, the agency has been notably hesitant to approve new treatments due to missteps with past approvals, together with most infamously, the diet medicine fen-phen, that was later found to cause probably fatal heart-valve issues.